$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021022902 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$0.00	$0.00	$5.000M
YoY Change	-100.0%	-100.0%	27677.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.551M	$2.504M	$2.080M
YoY Change	22.64%	21.55%	-11.86%
% of Gross Profit
Research & Development	$4.371M	$5.915M	$3.850M
YoY Change	13.53%	46.56%	95.43%
% of Gross Profit
Depreciation & Amortization	$41.00K	$38.00K	$110.0K
YoY Change	-62.73%	-65.45%	-15.38%
% of Gross Profit
Operating Expenses	$6.960M	$8.419M	$6.028M
YoY Change	15.46%	38.13%	35.37%
Operating Profit		-$8.419M
YoY Change		668.86%
Interest Expense	-$173.0K	$210.0K	-$290.0K
YoY Change	-40.34%	-54.94%	-36.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$7.133M	-$8.628M	-$1.320M
YoY Change	440.38%	466.51%	-73.01%
Income Tax	$0.00	$0.00	$10.00K
% Of Pretax Income
Net Earnings	-$7.133M	-$8.628M	-$1.322M
YoY Change	439.56%	466.14%	-72.98%
Net Earnings / Revenue			-26.44%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share	-$665.8K	-$0.10	-$27.60K
COMMON SHARES
Basic Shares Outstanding	87.05M shares	87.04M shares	39.16M shares
Diluted Shares Outstanding		87.04M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.38M	$35.85M	$31.10M
YoY Change	94.16%	101.39%	-8.8%
Cash & Equivalents	$60.38M	$35.80M	$31.09M
Short-Term Investments
Other Short-Term Assets	$1.780M	$1.066M	$1.826M
YoY Change	-2.52%	-0.93%	49.55%
Inventory
Prepaid Expenses	$3.010M	$3.010M	$3.314M
Receivables	$0.00	$0.00	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$65.24M	$39.99M	$36.73M
YoY Change	77.61%	52.0%	-9.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$281.0K	$277.0K	$472.0K
YoY Change	-40.47%	-51.74%	-48.75%
Goodwill
YoY Change
Intangibles	$83.00K	$89.00K	$125.0K
YoY Change	-33.6%	-31.01%	-53.01%
Long-Term Investments
YoY Change
Other Assets	$291.0K	$0.00	$24.00K
YoY Change	1112.5%	-100.0%	-95.07%
Total Long-Term Assets	$3.219M	$3.056M	$874.0K
YoY Change	268.31%	194.98%	-47.79%
TOTAL ASSETS
Total Short-Term Assets	$65.24M	$39.99M	$36.73M
Total Long-Term Assets	$3.219M	$3.056M	$874.0K
Total Assets	$68.45M	$43.04M	$37.60M
YoY Change	82.04%	57.42%	-10.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$285.0K	$586.0K	$535.0K
YoY Change	-46.73%	-46.82%	-59.5%
Accrued Expenses	$821.0K	$775.0K	$581.0K
YoY Change	41.31%	-28.83%	-24.55%
Deferred Revenue			$0.00
YoY Change			-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.668M	$4.700M
YoY Change	-100.0%	-65.68%	-68.46%
Total Short-Term Liabilities	$5.227M	$11.46M	$11.58M
YoY Change	-54.85%	-41.17%	-46.39%
LONG-TERM LIABILITIES
Long-Term Debt	$4.673M	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.179M	$2.570M	$0.00
YoY Change		2236.36%	-100.0%
Total Long-Term Liabilities	$5.852M	$2.570M	$0.00
YoY Change		2236.36%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.227M	$11.46M	$11.58M
Total Long-Term Liabilities	$5.852M	$2.570M	$0.00
Total Liabilities	$13.50M	$14.03M	$11.58M
YoY Change	16.57%	-28.38%	-47.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$454.9M	-$447.7M	-$427.0M
YoY Change	6.51%	5.17%	3.82%
Common Stock	$509.8M	$476.7M	$453.1M
YoY Change	12.52%	9.98%	5.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.96M	$29.01M	$26.03M
YoY Change
Total Liabilities & Shareholders Equity	$68.45M	$43.04M	$37.60M
YoY Change	82.04%	57.42%	-10.64%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$7.133M	-$8.628M	-$1.322M
YoY Change	439.56%	466.14%	-72.98%
Depreciation, Depletion And Amortization	$41.00K	$38.00K	$110.0K
YoY Change	-62.73%	-65.45%	-15.38%
Cash From Operating Activities	-$7.831M	-$5.562M	$3.190M
YoY Change	-345.49%	23.6%	-164.06%
INVESTING ACTIVITIES
Capital Expenditures	-$41.00K	-$26.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$41.00K	-$26.00K	$0.00
YoY Change		160.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	32.41M	-4.000K	10.05M
YoY Change	222.46%	-99.63%	-59.0%
NET CHANGE
Cash From Operating Activities	-7.831M	-5.562M	3.190M
Cash From Investing Activities	-41.00K	-26.00K	0.000
Cash From Financing Activities	32.41M	-4.000K	10.05M
Net Change In Cash	24.54M	-5.592M	13.24M
YoY Change	85.31%	0.22%	-32.0%
FREE CASH FLOW
Cash From Operating Activities	-$7.831M	-$5.562M	$3.190M
Capital Expenditures	-$41.00K	-$26.00K	$0.00
Free Cash Flow	-$7.790M	-$5.536M	$3.190M
YoY Change	-344.2%	23.02%	-164.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember
CY2020Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://www.regulusrx.com/20210930#RevenueUnderCollaborationsMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35670
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
	dei	Trading Symbol TradingSymbol	RGLS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4224 Campus Point Court, Suite 210
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	202-6300
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87047832	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35848000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31087000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	503000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3314000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1066000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1826000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	39986000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	36730000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	277000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	89000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	125000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2690000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2021Q3	us-gaap	Assets Assets	43042000	USD
CY2020Q4	us-gaap	Assets Assets	37604000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	586000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	535000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	775000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581000	USD
CY2021Q3	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	2347000	USD
CY2020Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1097000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1427000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1743000	USD
CY2021Q3	us-gaap	Debt Current DebtCurrent	4668000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	4652000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1657000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2970000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11460000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11578000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2570000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Liabilities	14030000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	11578000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1330832	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1330832	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Operating Expenses OperatingExpenses	18132000	USD
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87047832	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87047832	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67432712	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67432712	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	87000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	476643000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	453002000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-447720000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427045000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29012000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43042000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37604000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5006000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5006000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5915000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4036000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13385000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11396000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2504000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2059000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7471000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6736000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	8419000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	6095000	USD
	us-gaap	Operating Expenses OperatingExpenses	20856000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8419000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1095000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20856000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13126000	USD
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	1000	USD
CY2020Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	38000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	823000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	127000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	210000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	466000	USD
	us-gaap	Interest Expense InterestExpense	641000	USD
	us-gaap	Interest Expense InterestExpense	1416000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8628000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1523000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20674000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14415000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8628000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1524000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20675000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14408000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87042437	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87042437	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38137281	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38137281	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78560760	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78560760	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30695137	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30695137	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2021Q1	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	666000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5713000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	691000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6013000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	27111000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2021Q2	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	166000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14831000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	754000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-6034000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36828000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	807000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8628000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29012000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	823000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	14902000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	629000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6947000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	8584000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	692000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1524000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	7754000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20675000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14408000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	418000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	362000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2252000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2144000	USD
	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	662000	USD
	rgls	Gain Loss On Loan Forgiveness GainLossOnLoanForgiveness	0	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	39000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	148000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-503000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2859000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-304000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-536000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-784000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-145000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-219000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	193000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-208000	USD
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1250000	USD
	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	380000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-316000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-416000	USD
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	291000	USD
	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-112000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-729000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1212000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16297000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15725000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-210000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	0	USD
	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	662000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21384000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1000000	USD
	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	81000	USD
	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	207000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21330000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-542000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4823000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16278000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35910000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17843000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35848000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17843000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35910000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17843000	USD
	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	662000	USD
	rgls	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	329000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1066000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1000	USD
	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	505600000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35800000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Additionally, the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty.</span></div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28635276	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28635276	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25813032	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25813032	shares
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33904000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	26901000	USD
	rgls	Number Of Amendments NumberOfAmendments	8	amendment
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87047832	shares
CY2021Q3	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2020Q1	rgls	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Period For Yearly Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedPeriodForYearlyIncrease	P10Y
CY2019Q2	rgls	Number Of Closings NumberOfClosings	2	closing
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9727000	shares
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	91616000	shares
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	807000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	692000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2252000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2144000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	185000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	754000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	776000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	800000	USD
CY2021Q3	rgls	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	1101000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3616000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	471000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3145000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	575000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2570000	USD

Files In Submission

Name	View Source	Status
0001628280-21-022902-index-headers.html	Edgar Link	pending
0001628280-21-022902-index.html	Edgar Link	pending
0001628280-21-022902.txt	Edgar Link	pending
0001628280-21-022902-xbrl.zip	Edgar Link	pending
ex-311x20210930.htm	Edgar Link	pending
ex-312x20210930.htm	Edgar Link	pending
ex-321x20210930.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20210930.htm	Edgar Link	pending
rgls-20210930.xsd	Edgar Link	pending
rgls-20210930_cal.xml	Edgar Link	unprocessable
rgls-20210930_def.xml	Edgar Link	unprocessable
rgls-20210930_htm.xml	Edgar Link	completed
rgls-20210930_lab.xml	Edgar Link	unprocessable
rgls-20210930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2021 Q4 Form 10-Q Financial Statement

#000162828021022902 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2021 Q4 Form 10-Q Financial Statement

#000162828021022902 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls